Clinical Trial: Diagnostic Accuracy and Utility of ZTE Added to Routine MRI

U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07882147) titled 'Diagnostic Accuracy and Utility of ZTE Added to Routine MRI' on Oct. 12.

Brief Summary: Breast cancer is the most common cancer in women worldwide [1]. The burden is heaviest in low- and middle-income countries, where late detection, limited screening access and scarce biopsy resources delay diagnosis [2,3]. Accessible, non-invasive imaging that can triage patients accurately is therefore needed. Digital mammography and digital breast tomosynthesis are the reference tools for detecting microcalcifications, which are often the earliest visible sign of ductal carcinoma in situ (DCIS) and can appear before any mass or architectural dis...